ストックスクリーナーアプリを入手
2.88
1.03%
-0.03
前日終値:
$2.91
開ける：
$2.8
24時間の取引高:
900.23K
Relative Volume:
0.74
時価総額：
$171.59M
収益：
-
当期純損益:
$-36.95M
株価収益率:
-3.4286
EPS:
-0.84
ネットキャッシュフロー:
$-33.46M
1週間 パフォーマンス:
+7.46%
1か月 パフォーマンス:
+53.60%
6か月 パフォーマンス:
-53.32%
1年 パフォーマンス:
-70.28%
1日の値動き範囲:
$2.75
$2.94
1週間の範囲:
$2.485
$3.23
52週間の値動き範囲:
$1.61
$11.20
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
LRMR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
2.88 | 171.59M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | 開始されました | Truist | Buy |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-10-03 | 開始されました | Wedbush | Outperform |
| 2024-10-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-03 | 開始されました | Leerink Partners | Outperform |
| 2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-19 | 開始されました | Guggenheim | Buy |
| 2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World
Northern Trust Corp Acquires 14,185 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential - MSN
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock By Investing.com - Investing.com South Africa
Larimar Therapeutics’ SWOT analysis: nomlabofusp’s potential lifts FA stock - Investing.com
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments - MyChesCo
Larimar Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Larimar Therapeutics Advances Nomlabofusp Amid Financial Loss - TipRanks
Larimar Therapeutics Inc (NASDAQ: LRMR): Can A Stock Be -26.10% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
The time has not yet come to remove your chips from the table: Larimar Therapeutics Inc (LRMR) - Sete News
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Humana (HUM) and Larimar Therapeutics (LRMR) - The Globe and Mail
Stock Traders Buy High Volume of Call Options on Larimar Therapeutics (NASDAQ:LRMR) - Defense World
LRMR: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Larimar Therapeutics Inc (LRMR)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Larimar: Q1 Earnings Snapshot - MySA
Larimar Therapeutics, Inc. SEC 10-Q Report - TradingView
Investor’s Delight: Larimar Therapeutics Inc (LRMR) Closes Strong at 2.39, Up 1.70 - DWinneX
Larimar (LRMR) Advances Clinical Program Towards Potential FDA A - GuruFocus
Investing in Larimar Therapeutics Inc (LRMR) Is Getting More Attractive - knoxdaily.com
Larimar (LRMR) Advances Clinical Program Towards Potential FDA Approval | LRMR Stock News - GuruFocus
Larimar Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Larimar's Friedreich's Ataxia Drug Gets FDA Accelerated Approval Path While Cash Reserves Surge - Stock Titan
Larimar Therapeutics awards key executives performance-based stock - MSN
Market Watch Highlights: Larimar Therapeutics Inc (LRMR) Ends on an Upturn Note at 2.38 - DWinneX
Larimar Therapeutics Inc (LRMR) Stock: A Comprehensive 52-Week Review - investchronicle.com
Nothing is Better Than Larimar Therapeutics Inc (LRMR) stock at the moment - Sete News
The Potential Rise in the Price of Larimar Therapeutics Inc (LRMR) following insiders activity - knoxdaily.com
Larimar Therapeutics Inc (LRMR)’s results reveal risk - uspostnews.com
Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts - Seeking Alpha
An In-Depth Look at Larimar Therapeutics Inc Inc. (LRMR) Price Performance During Market Crashes - investchronicle.com
Larimar to seek accelerated approval of FA therapy nomlabofusp this year - Friedreich's Ataxia News
Q1 EPS Estimate for Larimar Therapeutics Lowered by Analyst - MarketBeat
Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth? - Yahoo Finance
Larimar Therapeutics Advances Nomlabofusp Program Amid Regulatory Support - MSN
Larimar Therapeutics (NASDAQ:LRMR) Given Buy Rating at Guggenheim - Defense World
HC Wainwright Issues Positive Forecast for Larimar Therapeutics (NASDAQ:LRMR) Stock Price - Defense World
Larimar Therapeutics Inc (NASDAQ: LRMR) Shares Might Go Down -73.01% This Year - Marketing Sentinel
Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $10.00 by Analysts at Robert W. Baird - Defense World
Jones Trading maintains $14 target on Larimar Therapeutics stock By Investing.com - Investing.com UK
Larimar Therapeutics Reports 2024 Financial Results and Development Progress - TipRanks
FDA open to new surrogate endpoint for FA drug approval By Investing.com - Investing.com Australia
Larimar: Q4 Earnings Snapshot - mySA
Wedbush Cuts Price Target on Larimar Therapeutics to $17 From $22, Maintains Outperform Rating - MarketScreener
FDA open to new surrogate endpoint for FA drug approval - Investing.com India
Larimar: Q4 Earnings Snapshot -March 24, 2025 at 07:17 am EDT - MarketScreener
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
1.91%
1.17%
大文字化:
|
ボリューム (24 時間):